Dave Muoio

Also: HomeStay to distribute, integrate G Medical's remote monitoring tech; Imprivata and Microsoft announce new health IT security offerings.

In response to recent COVID-19 guidance, the company is releasing its video game-like treatment to qualifying families at no cost, and without explicitly requiring a doctor's prescription.

One Drop recently announced the acquisition of Sano's assets, IP and a portion of its staff.

Using a designated kit ordered by a doctor, patients will be able to self-swab and mail their samples to LabCorp testing facilities. The self-collection kits will be available in "most states" in the coming weeks.

Also: RDMD locks in $14M for rare disease therapy research; VIDA Diagnostics raises $11M for AI lunch imaging analysis.

Alongside the purchase of Amblyotech, the pharma company announced upcoming collaborations with major video game publisher Ubisoft and McGill University.

The COVID-19 Telehealth Program and the Connected Care Pilot Program together are set to invest $300 million so that healthcare providers can reach the patients in greatest need of virtual-care services. 

Also: Mercom's Q1 2020 digital health funding report; Fitbit, Scripps, Stanford collaborate on COVID-19 detection research.

A new guidance from the U.S. regulator relaxes a handful of requirements for these digital health devices, and clarifies the agency's long-term enforcement policy for low-risk wellness products. 

Many are anticipating greater adoption of digital health services and more favorable regulatory and reimbursement environments, according to a recent poll sampling 513 digital health and adjacent companies.